^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Oral Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/08/2021
    Excerpt:
    PRINCIPLES OF SYSTEMIC THERAPY FOR NON-NASOPHARYNGEAL CANCERS (Lip, Oral Cavity, Oropharynx, Hypopharynx, Glottic Larynx, Supraglottic Larynx, Ethmoid Sinus, Maxillary sinus, Occult Primary)...Other Recommended Regimens...Pembrolizumab/platinum (cisplatin or carboplatin)/docetaxel
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    PRINCIPLES OF SYSTEMIC THERAPY FOR NON-NASOPHARYNGEAL CANCERS...(Lip, Oral Cavity, Oropharynx, Hypopharynx, Glottic Larynx, Supraglottic Larynx, Ethmoid Sinus, Maxillary Sinus, Occult Primary)...Preferred Regimens...First-line...Subsequent-Line (if not previously used) Pembrolizumab
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    PRINCIPLES OF SYSTEMIC THERAPY FOR NON-NASOPHARYNGEAL CANCERS...(Lip, Oral Cavity, Oropharynx, Hypopharynx, Glottic Larynx, Supraglottic Larynx, Ethmoid Sinus, Maxillary Sinus, Occult Primary)...Preferred Regimens...First-line...Pembrolizumab/platinum (cisplatin or carboplatin)/5-FU...Pembrolizumab/platinum (cisplatin or carboplatin)/docetaxel...Pembrolizumab/platinum (cisplatin or carboplatin)/paclitaxel
    Secondary therapy:
    carboplatin + 5-fluorouracil; carboplatin + paclitaxel; cisplatin + paclitaxel; carboplatin + docetaxel; cisplatin + 5-fluorouracil; cisplatin + docetaxel